Search
Now showing items 1-6 of 6
Seroprevalence of West Nile Virus among Healthy Blood Donors from Different National Populations Residing in Qatar
(
Elsevier
, 2020 , Article)
ObjectiveTo estimate the age- and nationality-specific West Nile virus (WNV) seroprevalence in select Middle East and North Africa (MENA) populations residing in Qatar. MethodsSera were collected from male blood donors ...
Demographics and Epidemiology of Hepatitis B in the State of Qatar: A Five-Year Surveillance-Based Incidence Study
(
MDPI
, 2019 , Article)
Background: Expatriates represent >80% of Qatar’s population, mostly arriving from countries in Africa and Asia that are endemic with many diseases. This increases the risk for introducing new pathogens into the country ...
Prevalence and molecular profiling of Epstein Barr virus (EBV) among healthy blood donors from different nationalities in Qatar.
(
Public Library of Science
, 2017 , Article)
The Epstein-Barr virus (EBV) is the causative agent of infectious mononucleosis. EBV is highly prevalent lymphotropic herpesvirus and has been linked to several malignancies. Transmission is generally by oral secretions, ...
Seroprevalence of herpes simplex virus type 1 and type 2 among the migrant workers in Qatar
(
Springer
, 2023 , Article)
Background: Limited data exists on herpes simplex virus type 1 (HSV-1) and type 2 (HSV-2) infections in migrant populations. This study investigated HSV-1 and HSV-2 seroprevalences and associations among craft and manual ...
SARS-CoV-2 infection and effects of age, sex, comorbidity, and vaccination among older individuals: A national cohort study
(
Wiley
, 2023 , Article)
Background: We investigated the contribution of age, coexisting medical conditions, sex, and vaccination to incidence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and of severe, critical, or ...
Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB* infections
(2023 , Article)
In October of 2022, Qatar introduced COVID-19 bivalent vaccination for persons ≥ 12 years using the 50-μg mRNA-1273.214 vaccine combining SARS-CoV-2 ancestral and omicron BA.1 strains.1 We estimated this vaccine’s effectiveness ...